Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation

Pankaj K Singh; Amit A Deorukhkar; Bhanu P Venkatesulu; Xiaolin Li; Ramesh Tailor; John S. Bomalaski; Sunil Krishnan

doi:10.1158/1535-7163.MCT-18-0708

Research Article

Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation

Pankaj K Singh, Amit A Deorukhkar, Bhanu P Venkatesulu, Xiaolin Li, Ramesh Tailor, John S. Bomalaski and Sunil Krishnan

Pankaj K Singh

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amit A Deorukhkar

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bhanu P Venkatesulu

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Xiaolin Li

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ramesh Tailor

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John S. Bomalaski

Medical Affairs, Polaris Group (United States)

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sunil Krishnan

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: skrishnan@mdanderson.org

DOI: 10.1158/1535-7163.MCT-18-0708

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Additional Files

Supplementary Data

Figure S1 - Experimental Plan
Figure S2 - MTS assay and clonogenic
Figure S3 - RPPA data
Figure S4 - BPI colocalization
Figure S5 - Ki67 and VEGF
Figure S6 - SiRNA
Figure S7 - Cell cycle

Published OnlineFirst August 8, 2019
doi: 10.1158/1535-7163.MCT-18-0708

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

Citation Tools

Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation

Pankaj K Singh, Amit A Deorukhkar, Bhanu P Venkatesulu, Xiaolin Li, Ramesh Tailor, John S. Bomalaski and Sunil Krishnan

Mol Cancer Ther August 8 2019 DOI: 10.1158/1535-7163.MCT-18-0708

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Exploiting arginine auxotrophy with pegylated arginine deiminase (ADI-PEG20) to sensitize pancreatic cancer to radiotherapy via metabolic dysregulation